Hello, and welcome to Virtual Investor Conferences. On behalf of the Life Sciences Investor Forum and our co-host Zacks Small Cap Research, we're very pleased you joined us for our quarterly ...

The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 ...

VANQUISH-1 and VANQUISH-2 Studies to Evaluate Subcutaneous VK2735 in Obese Adults with and without Type 2 Diabetes SAN DIEGO, June 25, 2025 /PRNewswire/ ...

Diabetes drug Ozempic and weight-loss jab Wegovy may also reduce the risk of dementia, according to a new study. American ...

BERKELEY HEIGHTS, NJ, USA and SHANGHAI, China I June 23, 2025 I Corxel Pharmaceuticals Limited (CORXEL), a clinical-stage ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly one-quarter of their body weight in early trials.

The next generation of diabetes and weight loss drugs could come in pill form, deliver even greater weight loss results, and ...

In June 2025, Carmot Therapeutics Inc. announced a Phase 2 Study to Evaluate the Efficacy, Safety, and Tolerability of ...

A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.

Biomea Fusion Inc. has released preclinical findings from a 28-day weight loss study in obese nonhuman primates evaluating ...

The biotech had also “started to get some traction” on a triple-action molecule that could activate GLP-1, GIP and glucagon simultaneously. Septerna has shared (PDF) mouse data on the GIP ...

Collaboration combines Novo Nordisk’s scientific leadership in obesity and cardiometabolic diseases with Septerna’s expertise in G protein-coupled receptor (GPCR) drug discovery Goal is to ...